QuidelOrtho Eyes $1.5B Sale of COVID-Era Rapid Testing Business
The unit, once a pandemic star, attracts strong private equity interest.
/ 1648 items
#XY↓
Palisade Bio Stock Surges on Positive FDA Clearance for Next-Gen IBD Therapy
The FDA has cleared Palisade Bio’s investigational new drug application for PALI-2108. The company will now start its Phase 2 ASCENTRA-UC trial in H2 2026.
BofA Downgrades Biohaven to Underperform, Cuts Price Target to $11 on Kv7 Risks
Analyst highlights competition risk in Kv7 epilepsy program and cuts peak sales forecast.
Evommune’s EVO756 Fails Phase 2b Trial in Chronic Spontaneous Urticaria, Development Discontinued
Evommune reported EVO756 failed to meet its primary endpoint in the Phase 2b CSU trial. The company is discontinuing development in urticaria but advancing the drug in atopic dermatitis with data expected in Q3 2026.
Nomlabofusp Shows 100% Frataxin Response in Friedreich’s Ataxia — But Anaphylaxis Risk Weighs on Shares
Positive long-term data for Larimar’s nomlabofusp in Friedreich’s ataxia: 100% frataxin response and walking recovery signals. FDA accelerated pathway opens, but safety issues weigh on stock.
Zymeworks to Acquire Theravance Biopharma for $17 Per Share in Cash Plus CVR
The deal adds YUPELRI to Zymeworks’ portfolio.